insights_auto
Why is LYEL up 6.39%?
Dive Deeperchevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
$ 7.99
arrow_upward
+6.39%(+0.48) 1D
10-р сарын 14, 16:00:01 (GMT-4) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
$ 7.42
High
$ 8.28
Low
$ 7.20
Mkt. cap
195.80 сая
Avg. vol.
138.33 мян
Volume
402.24 мян
52-wk high
$ 45.00
52-wk low
$ 7.20
EPS
-$ 12.01
Beta
-0.03
Shares outstanding
24.50 сая
No. of employees
161
Open
$ 7.42
High
$ 8.28
Low
$ 7.20
Mkt. cap
195.80 сая
Avg. vol.
138.33 мян
Volume
402.24 мян
52-wk high
$ 45.00
52-wk low
$ 7.20
EPS
-$ 12.01
Beta
-0.03
Shares outstanding
24.50 сая
No. of employees
161
News stories
From web sources and news partners
Investing.com Nigeria
·
21 цагийн өмнө
Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com
Stock Titan
·
1 өдрийн өмнө
An automatic tax-cover sale leaves Lyell Immunopharma (LYEL) medical chief holding 19,857 shares.
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Websitelyell.com